152 related articles for article (PubMed ID: 36233089)
21. Haplotype analysis on relationship of ERCC2 and ERCC3 gene polymorphisms with osteosarcoma risk in Chinese young population.
Xu Q; Zhang Z; Sun W; Hu B
Mamm Genome; 2017 Jun; 28(5-6):227-233. PubMed ID: 28474168
[TBL] [Abstract][Full Text] [Related]
22. Role of ERCC2 and ERCC3 gene polymorphisms in the development of osteosarcoma.
Ma X; Zhang Y; Sun TS; Yao JH
Genet Mol Res; 2016 Mar; 15(1):. PubMed ID: 27051024
[TBL] [Abstract][Full Text] [Related]
23. Single nucleotide polymorphisms and expression of ERCC1 and ERCC2 vis-à-vis chemotherapy drug cytotoxicity in human glioma.
Chen H; Shao C; Shi H; Mu Y; Sai K; Chen Z
J Neurooncol; 2007 May; 82(3):257-62. PubMed ID: 17151930
[TBL] [Abstract][Full Text] [Related]
24. GTSE1 is possibly involved in the DNA damage repair and cisplatin resistance in osteosarcoma.
Xie C; Xiang W; Shen H; Shen J
J Orthop Surg Res; 2021 Dec; 16(1):713. PubMed ID: 34876170
[TBL] [Abstract][Full Text] [Related]
25. Platinum agents in the treatment of osteosarcoma: efficacy of cisplatin vs. carboplatin in human osteosarcoma cell lines.
Robson H; Meyer S; Shalet SM; Anderson E; Roberts S; Eden OB
Med Pediatr Oncol; 2002 Dec; 39(6):573-80. PubMed ID: 12376980
[TBL] [Abstract][Full Text] [Related]
26. Pharmacogenomics and Pharmacogenetics in Osteosarcoma: Translational Studies and Clinical Impact.
Hattinger CM; Patrizio MP; Luppi S; Serra M
Int J Mol Sci; 2020 Jun; 21(13):. PubMed ID: 32629971
[TBL] [Abstract][Full Text] [Related]
27. ERCC1 and ERCC2 variants predict survival in gastric cancer patients.
Li Y; Liu Z; Liu H; Wang LE; Tan D; Ajani JA; Wei QY
PLoS One; 2013; 8(9):e71994. PubMed ID: 24023723
[TBL] [Abstract][Full Text] [Related]
28. Overcoming glutathione S-transferase P1-related cisplatin resistance in osteosarcoma.
Pasello M; Michelacci F; Scionti I; Hattinger CM; Zuntini M; Caccuri AM; Scotlandi K; Picci P; Serra M
Cancer Res; 2008 Aug; 68(16):6661-8. PubMed ID: 18701490
[TBL] [Abstract][Full Text] [Related]
29. Establishment and characterization of a cisplatin‑resistant human osteosarcoma cell line.
Han T; Zhu X; Wang J; Zhao H; Ma Q; Zhao J; Qiu X; Fan Q
Oncol Rep; 2014 Sep; 32(3):1133-9. PubMed ID: 25017716
[TBL] [Abstract][Full Text] [Related]
30. Long Non-coding RNAs in Cisplatin Resistance in Osteosarcoma.
Ferretti VA; León IE
Curr Treat Options Oncol; 2021 Mar; 22(5):41. PubMed ID: 33745006
[TBL] [Abstract][Full Text] [Related]
31. Genome sequencing analysis of blood cells identifies germline haplotypes strongly associated with drug resistance in osteosarcoma patients.
Bhuvaneshwar K; Harris M; Gusev Y; Madhavan S; Iyer R; Vilboux T; Deeken J; Yang E; Shankar S
BMC Cancer; 2019 Apr; 19(1):357. PubMed ID: 30991985
[TBL] [Abstract][Full Text] [Related]
32. Suppressing CHD1L reduces the proliferation and chemoresistance in osteosarcoma.
Fan GT; Ling ZH; He ZW; Wu SJ; Zhou GX
Biochem Biophys Res Commun; 2021 May; 554():214-221. PubMed ID: 33813077
[TBL] [Abstract][Full Text] [Related]
33. Pharmacogenomics of second-line drugs used for treatment of unresponsive or relapsed osteosarcoma patients.
Hattinger CM; Vella S; Tavanti E; Fanelli M; Picci P; Serra M
Pharmacogenomics; 2016 Dec; 17(18):2097-2114. PubMed ID: 27883291
[TBL] [Abstract][Full Text] [Related]
34. ERCC1 C8092A (rs3212986) polymorphism as a predictive marker in esophageal cancer patients treated with cisplatin/5-FU-based neoadjuvant therapy.
Rumiato E; Cavallin F; Boldrin E; Cagol M; Alfieri R; Basso D; Castoro C; Ancona E; Amadori A; Ruol A; Saggioro D
Pharmacogenet Genomics; 2013 Nov; 23(11):597-604. PubMed ID: 23962907
[TBL] [Abstract][Full Text] [Related]
35. Notch pathway inhibition using DAPT, a γ-secretase inhibitor (GSI), enhances the antitumor effect of cisplatin in resistant osteosarcoma.
Dai G; Deng S; Guo W; Yu L; Yang J; Zhou S; Gao T
Mol Carcinog; 2019 Jan; 58(1):3-18. PubMed ID: 29964327
[TBL] [Abstract][Full Text] [Related]
36. XPD c.934G>A polymorphism of nucleotide excision repair pathway in outcome of head and neck squamous cell carcinoma patients treated with cisplatin chemoradiation.
Lopes-Aguiar L; Costa EF; Nogueira GA; Lima TR; Visacri MB; Pincinato EC; Calonga L; Mariano FV; de Almeida Milani Altemani AM; Altemani JM; Coutinho-Camillo CM; Ribeiro Alves MA; Moriel P; Ramos CD; Chone CT; Lima CS
Oncotarget; 2017 Mar; 8(10):16190-16201. PubMed ID: 26918827
[TBL] [Abstract][Full Text] [Related]
37. Do genetic polymorphisms modulate response rate and toxicity of Cisplatin associated with radiotherapy in laryngeal squamous cell carcinoma?: a case report.
Lopes-Aguiar L; Visacri MB; Nourani CML; Costa EFD; Nogueira GAS; Lima TRP; Pincinato EC; Moriel P; Altemani JMC; Lima CSP
Medicine (Baltimore); 2015 Apr; 94(16):e578. PubMed ID: 25906090
[TBL] [Abstract][Full Text] [Related]
38. Pharmacogenetics of oxaliplatin as adjuvant treatment in colon carcinoma: are single nucleotide polymorphisms in GSTP1, ERCC1, and ERCC2 good predictive markers?
Fariña Sarasqueta A; van Lijnschoten G; Lemmens VE; Rutten HJ; van den Brule AJ
Mol Diagn Ther; 2011 Oct; 15(5):277-83. PubMed ID: 21958378
[TBL] [Abstract][Full Text] [Related]
39. Prognostic value of ERCC1 and ERCC2 gene polymorphisms in patients with gastric cancer receiving platinum-based chemotherapy.
Mo J; Luo M; Cui J; Zhou S
Int J Clin Exp Pathol; 2015; 8(11):15065-71. PubMed ID: 26823845
[TBL] [Abstract][Full Text] [Related]
40. PPARγ Agonist Pioglitazone in Combination With Cisplatinum Arrests a Chemotherapy-resistant Osteosarcoma PDOX Model.
Higuchi T; Yamamoto J; Sugisawa N; Tashiro Y; Nishino H; Yamamoto N; Hayashi K; Kimura H; Miwa S; Igarashi K; Bouvet M; Singh SR; Tsuchiya H; Hoffman RM
Cancer Genomics Proteomics; 2020; 17(1):35-40. PubMed ID: 31882549
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]